Status epilepticus: New concepts

Current Opinion in Neurology

Volumn 12, Issue 2, 1999, Pages 183-190

  Alldredge, Brian K ^a,b   Lowenstein, Daniel H ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; DIAZEPAM; FOSPHENYTOIN SODIUM; LORAZEPAM; MIDAZOLAM; NEURON SPECIFIC ENOLASE; PHENOBARBITAL; PHENYTOIN; PROPOFOL; VALPROIC ACID;

ACIDOSIS; BUCCAL DRUG ADMINISTRATION; CEREBROSPINAL FLUID LEVEL; CLINICAL TRIAL; DRUG INFUSION; DRUG SENSITIVITY; ELECTROENCEPHALOGRAM; EMERGENCY MEDICINE; ENZYME BLOOD LEVEL; EPILEPTIC STATE; GENETIC PREDISPOSITION; HEART FAILURE; HUMAN; HYPOXIA; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL GENETICS; META ANALYSIS; MOLECULAR BIOLOGY; NERVE CELL LESION; NEUROMODULATION; NONHUMAN; OUTCOMES RESEARCH; PARAMEDICAL EDUCATION; PATIENT CARE; PATIENT MONITORING; RECTAL DRUG ADMINISTRATION; RECURRENCE RISK; REVIEW; RHABDOMYOLYSIS; SEIZURE; SIDE EFFECT; SUBLINGUAL DRUG ADMINISTRATION;

EID: 0032947761     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199904000-00009     Document Type: Review

References (53)

1. Tasker RC. Emergency treatment of acute seizures and status epilepticus. Arch Dis Child 1998; 79:78-83.
2. Scott RC, Surtees RA, Neville BG. Status epilepticus: pathophysiology, epidemiology, and outcomes. Arch Dis Child 1998; 79:73-77.
3. Weise KL, Bleck TP. Status epilepticus in children and adults. Crit Care Clin 1997; 13:629-646.
4. Shorvon S. Status epilepticus: its clinical features and treatment in children and adults. Cambridge: Cambridge University Press; 1994. A superb textbook that provides a remarkably comprehensive review of our current understanding of the epidemiology, pathophysiology, clinical features and therapies for status epilepticus.
5. Lowenstein DH, Alldredge BK. Status epilepticus. N Eng J Med 1998;338:970-976. This and [6••] provides a very up-to-date review of clinical aspects of status epilepticus.
6. Walker MC. The epidemiology and management of status epilepticus. Curr Opin Neurol 1998; 11:149-154. See [5••].
7. Perl TM, Bedard L, Kosatsky T, Hockin JC, Todd EC, Remis RS. An outbreak of toxic encephalopathy caused by eating mussels contaminated with domoic acid. N Engl J Med 1990; 322:1775-1780. This and [8•] are important papers documenting the neurologic effects of poisoning by domoic acid, a structural analogue of kainic acid and glutamate. These observations in humans provide strong evidence for the concept that excitotoxicity accounts for some of the pathophysiological features seen in patients with temporal lobe epilepsy.
8. Teitelbaum JS, Zatorre RJ, Carpenter S, Gendron D, Evans AC, Gjedde A, Cashman NR. Neurologic sequelae of domoic acid intoxication due to the ingestion of contaminated mussels. N Engl J Med 1990; 322:1781-1787. See [7•].
9. Kapur J, Lothman EW. Loss of inhibition precedes delayed spontaneous seizures in the hippocampus after tetanic electrical stimulation. J Neurophysiol 1989; 61:427-434.
10. Kapur J, Stringer JL, Lothman EW. Evidence that repetitive seizures in the hippocampus cause a lasting reduction of GABAergic inhibition. J Neurophysiol 1989; 61:417-426.
11. A receptor function in CA1 pyramidal neurons. Ann Neurol 1995; 38:893-900.
12. A receptor are altered over time during status epilepticus.
13. A receptor both acutely and chronically after status epilepticus. A sophisticated combination of electrophysioogy and single-cell RNA amplification techniques were used in these studies.
14. Berkovic SF. Epilepsy genes and the genetics of epilepsy syndromes: the promise of new therapies based on genetic knowledge. Epilepsia 1997; 38 (Suppl 9):S32-S36.
15. Berkovic SF, Scheffer IE. Genetics of human partial epilepsy. Curr Opin Neurol 1997; 10:110-114.
16. Ferraro TN, Golden GT, Smith GG, Berrettini WH. Differential susceptibility to seizures induced by systemic kainic acid treatment in mature DBA/2J and C57BL/J6 mice. Epilepsia 1995; 36:301-307.
17. Ferraro TN, Golden GT, Smith GG, Schork NJ, St. Jean R Ballas C, et al. Mapping murine loci for seizure response to kainic acid. Mammalian Genome 1997; 8:200-208.
18. Schauwecker PE, Steward O. Genetic determinants of susceptibility to excitotoxic cell death: implications for gene targeting approaches. Proc Natl Acad Sci U S A 1997; 94:4103-4108.
19. van Domburg PH, Gabreels-Festen AA, Gabreels FJ, de Coo R, Ruitenbeek W, Wesseling P, ter Laak H. Mitochondrial cytopathy presenting as hereditary sensory neuropathy with progressive external ophthalmoplegia, ataxia and fatal myoclonic epileptic status. Brain 1996; 119:997-1010.
20. Inoue Y, Fujiwara T, Matsuda K, Kubota H, Tanaka M, Yagi K, et al. Ring chromosome 20 and nonconvulsive status epilepticus. Brain 1997; 120:939-953.
21. Corey LA, Pellock JM, Boggs JG, Miller LL, DeLorenzo RJ. Evidence for a genetic predisposition for status epilepticus. Neurology 1998;50:558-560. Using data from a twin registry, the authors provide a very compelling data in support of a genetics basis for status epilepticus in some patients.
22. Correale J, Rabinowicz AL, Heck CN, Smith TO, Loskota WJ, DeGiorgio CM. Status epilepticus increases CSF levels of neuron-specific enolase and alters the blood-brain barrier. Neurology 1998; 50:1388-1391.
23. Roine RO, Somer H, Kaste M, Viinikka L, Karonen SL. Neurological outcome after out-of-hospital arrest. Arch Neurol 1989; 46:753-756.
24. Karkela J, Bock E, Kaukinen S. CSF and serum brain-specific creatine kinase isoenzyme (CK-BB), neuron-specific enolase (NSE) and neural cell adhesion molecule (NCAM) as prognostic markers for hypoxic brain injury after cardiac arrest in man. J Neurol Sci 1993; 116:100-109.
25. DeGiorgio CM, Correale JD, Gott PS, Ginsburg DL, Bracht KA, Smith T, et al. Serum neuron-specific enolase in human status epilepticus. Neurology 1995; 45:1134-1137. The first prospective analysis of serum neuron specific anolase in patients with various forms of status epilepticus.
26. DeGiorgio CM, Gott PS, Rabinowicz AL, Heck CN, Smith TD, Correale JD. Neuron-specific enolase, a marker of acute neuronal injury, is increased in complex partial status epilepticus. Epilepsia 1996; 37:606-609.
27. Shaner DM, McCurdy SA, Herring MO, Gabor AJ. Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin. Neurology 1988; 38:202-207.
28. Leppik IE, Derivan AT, Homan RW, Walker J, Ramsay RE, Patrick B. Double-blind study of lorazepam in status epilepticus. JAMA 1983; 249:1452-1454.
29. Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ, et al. A comparison of four treatments for generalized convulsive status epilepticus. N Engl J Med 1998; 339:792-798. This is a large, well-controlled and important clinical trial. The major limitation in its clinical relevance is the lack of inclusion of a regimen consisting of lorazepam followed by phenytoin.
30. Sharbrough FW, Cascino GD, Hesdorffer D, Logroscino G, Hauser WA. The treatment of nonfebrile status epilepticus in Rochester, Minnesota, 1965-1984 [abstract]. Epilepsia 1998; 39 (Suppl 6):220.
31. Walker MD, Howard RS, Smith SJ, Miller DH, Shorvon SD. Diagnosis and treatment of status epilepticus on a neurological intensive care unit. Q J Med 1996; 89:913-920.
32. DeLorenzo RL, Waterhouse EJ, Towne AR, Boggs JG, Ko D, DeLorenzo GA, et al. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia 1998; 39:833-840. In most clinical practice and drug trials, status epilepticus is judged to have ceased when convulsions stop. This study demonstrates that electroencephalographic monitoring is needed to confirm that seizures have ceased.
33. Wheless JW, Venkataraman V. Safety of high I.V. loading doses of valproate [abstract]. Epilepsia 1998; 39 (Suppl 6):50. In this abstract from the 1998 American Epilepsy Society meeting, the authors report that the rate-limiting factor in the rate of intravenous valproate administration is the volume of the diluted infusion solution.
34. Czapinski P, Terczynski A. Intravenous valproic acid administration in status epilepticus [in Polish]. Neurol Neurochirurg Polska 1998; 32:11-22. Response of status epilepticus to drug treatment is usually much more favorable in open-label, uncontrolled studies (as it is in this study) than in rigorously designed clinical trials (e.g. [29••]). More research with intravenous valproate is required to validate these authors' results.
35. Giroud M, Gras D, Escousse A, Dumas R, Venaud G. Use of injectible valproic acid in status epilepticus: a pilot study. Drug Invest 1993; 5:154-159.
36. Lowe MR, DeToledo JC, Vilavizza N, Ramsay RE. Efficacy, safety, and tolerability of fast i.v. loading of valproate in patients with seizures and status epilepticus. Epilepsia 1998; 39 (Suppl 6):235.
37. Brown LA, Levin GM. Role of propofol in refractory status epilepticus. Ann Pharmacother 1998; 32:1053-1059.
38. Yaffe K, Lowenstein DH. Prognostic factors of pentobarbital therapy for refractory generalized status epilepticus. Neurology 1993; 43:895-900.
39. Stecker MM, Kramer TH, Raps EC, O'Meeghan R, Dulaney E, Skaar DJ. Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. Epilepsia 1998; 39:18-26. The small sample size of this retrospective study limit the authors' ability to detect differences in important outcome measures such as hypotension and time from discontinuation of treatment to extubation. Some hold the opinion that propfol is favored over pentobarbital with regard to these measures. Confirmation from controlled trials is lacking, however.
40. Crouteau D, Shevell M, Rosenblatt B, Dilenge ME, Andermann F. Treatment of absence status in the Lennox-Gastaut syndrome with propofol. Neurology 1998; 51:315-316.
41. Parke TJ, Stevens JE, Rice ASC, Greenaway CL, Bray RJ, Smith PJ, et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. Br Med J 1992; 305:613-616.
42. Hanna JP, Ramundo ML. Rhabdomyolysis and hypoxia associated with prolonged propofol infusion in children. Neurology 1998; 50:301-303.
43. Alldredge BK, Wall DB, Ferriero DM. Effect of prehospital treatment on the outcome of status epilepticus in children. Pediatr Neurol 1995; 12:213-216.
44. Alldredge BK, Gelb AM, Lowenstein DH. The effect of prehospital treatment of status epilepticus on subsequent patient management. Neurology 1992; 42 (Suppl 3):400.
45. Goldberg A. Delay in the treatment of patients with acute seizure episodes [abstract]. Epilepsia 1998; 39 (Suppl 6):109-110.
46. Alldredge B, Geib A, Isaacs M, Ulrich SK, Allen F, Segal M, et al. Prehospital treatment of status epilepticus. Neurology 1995; 45 (Suppl 4):A390.
47. Mitchell WG. Status epilepticus and acute repetitive seizures in children, adolescents, and young adults: etiology, outcome, and treatment. Epilepsia 1996; 37 (Suppl 1):S74-S80.
48. Morton LD, Rizkallah E, Pellock JM. New drug therapy for acute seizure management. Semin Pediatr Neurol 1997; 4:51-63.
49. O'Regan ME, Brown JK, Clarke M. Nasal rather than rectal benzodiazepines in the management of acute childhood seizures? Dev Med Child Neurol 1996; 38:1037-1045.
50. Scott RC, Besag FMC, Boyd SG, Berry D, Neville BGR. Buccal absorption of midazolam: pharmacokinetics and EEG pharmacodynamics. Epilepsia 1998; 39:290-294.
51. Cloyd JC, Lalonde RL, Beniak TE, Novack GD. A single-blind, crossover comparison of the pharmacokinetics and cognitive effects of a new diazepam rectal gel with intravenous diazepam. Epilepsia 1998; 39:520-526. The authors demonstrate that the rate of diazepam absorption from the gel formulation is sufficiently rapid to suggest utility in the management of status epilepticus. What is still unclear is whether the rate of drug absorption differs between rectal administration of the gel versus rectal administration of the intravenous solution.
52. Scott RC, Besag FM, Neville BG. Buccal midazolam or rectal diazepam for the acute treatment of seizures? Epilepsia 1998; 39 (Suppl 6):235.
53. Dreifuss FE, Rosman NP, Cloyd JC, Pellock JM, Kuzniecky RI, Lo WD, et al. A comparison of rectal diazepam gel and placebo for acute repetitive seizures. N Engl J Med 1998; 338:1869-1875.